Partial reduction of interleukin-33 signaling improves senescence and renal injury in diabetic nephropathy

Abstract

Diabetic nephropathy (DN) is a frequent and costly complication of diabetes with limited understandings of mechanisms and therapies. Emerging evidence points to the important roles of interleukin-33 (IL-33) in acute kidney injury, yet its contribution to DN is still unclear. We here found a ubiquitous increase of IL-33 and its receptor (ST2) in murine models and patients with DN. Surprisingly, both IL-33 and ST2 knockdown aggravated renal lesions in DN, while overexpression of IL-33 also exacerbated the condition. Further population-based analyses revealed a positive correlation of IL-33 expression with renal dysfunction in DN patients. Individuals with high IL-33 expression-related polygenic risk score had a higher DN risk. These findings confirmed the harmful effects of IL-33 on DN. Conversely, endogenous and exogenous partial reduction of IL-33 signaling conferred renoprotective effects in vivo and in vitro. Mechanistically, IL-33 induced senescence by regulating cell cycle factors in HK-2 cells, and accordingly senescence led to renal cell damage through the secretion of senescence-related secretory phenotype (SASP) including IL-33 and prostaglandins. Together, elevated IL-33 accelerates cellular senescence to drive DN possibly by SASP production, while a partial blockage improves renal injury and senescence. Our findings pinpoint a possible and new avenue for DN interventions.

Keywords

cellular senescence / diabetic nephropathy / interleukin-33 / senescence-related secretory phenotype

References

[1] Cao R, Tian H, Zhang Y, et al. Signaling pathways and intervention for therapy of type 2 diabetes mellitus. MedComm. 2023; 4(3): e283.

[2] Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022; 102(2): 248-260.

[3] DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021; 17(5): 319-334.

[4] Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018; 281(1): 154-168.

[5] Li T, Zhang Z, Bartolacci JG, et al. Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection. J Clin Invest. 2020; 130(10): 5397-5412.

[6] Lin Y, Xiao L, Cai Q, et al. The chemerin-CMKLR1 axis limits thermogenesis by controlling a beige adipocyte/IL-33/type 2 innate immunity circuit. Sci Immunol. 2021; 6(61).

[7] Wu MX, Wang SH, Xie Y, et al. Interleukin-33 alleviates diabetic cardiomyopathy through regulation of endoplasmic reticulum stress and autophagy via insulin-like growth factor-binding protein 3. J Cell Physiol. 2021; 236(6): 4403-4419.

[8] He Z, Song Y, Yi Y, et al. Blockade of IL-33 signalling attenuates osteoarthritis. Clin Transl Immunol. 2020; 9(10): e1185.

[9] Yang F, Zhu P, Duan L, Yang L, Wang J. IL-33 and kidney disease (Review). Mol Med Rep. 2016; 13(1): 3-8.

[10] Cao Q, Wang Y, Niu Z, et al. Potentiating tissue-resident type 2 innate lymphoid cells by IL-33 to prevent renal ischemia-reperfusion injury. J Am Soc Nephrol. 2018; 29(3): 961-976.

[11] Akcay A, Nguyen Q, He Z, et al. IL-33 exacerbates acute kidney injury. J Am Soc Nephrol. 2011; 22(11): 2057-2067.

[12] Ferhat M, Robin A, Giraud S, et al. Endogenous IL-33 contributes to kidney ischemia-reperfusion injury as an alarmin. J Am Soc Nephrol. 2018; 29(4): 1272-1288.

[13] Tonacci A, Quattrocchi P, Gangemi S. IL33/ST2 axis in diabetic kidney disease: a literature review. Medicina (Kaunas). 2019; 55(2).

[14] Fang Y, Chen B, Gong AY, et al. The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults. Kidney Int. 2021; 100(5): 1037-1053.

[15] Chen L, Mei G, Jiang C, et al. Carbon monoxide alleviates senescence in diabetic nephropathy by improving autophagy. Cell Prolif. 2021; 54(6): e13052.

[16] Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016; 530(7589): 184-189.

[17] Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, Shankland SJ. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int. 1999; 56(5): 1691-1699.

[18] Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int. 2005; 68(4): 1583-1589.

[19] Xu L, Wei C, Chen Y, et al. IL-33 induces thymic involution-associated naive T cell aging and impairs host control of severe infection. Nat Commun. 2022; 13(1): 6881.

[20] Yamagishi R, Kamachi F, Nakamura M, et al. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma. Sci Immunol. 2022; 7(72): eabl7209.

[21] Goldberg EL, Shchukina I, Youm YH, et al. IL-33 causes thermogenic failure in aging by expanding dysfunctional adipose ILC2. Cell Metab. 2021; 33(11): 2277-2287.e5.

[22] Wang D, Li Y, Wang N, et al. 1α 25-Dihydroxyvitamin D(3) prevents renal oxidative damage via the PARP1/SIRT1/NOX4 pathway in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab. 2020; 318(3): E343-e356.

[23] Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020; 32(3): 404-419.e6.

[24] Allegra A, Innao V, Tartarisco G, et al. The ST2/interleukin-33 axis in hematologic malignancies: the IL-33 paradox. Int J Mol Sci. 2019; 20(20).

[25] Xiong Y, Zhou L. The signaling of cellular senescence in diabetic nephropathy. Oxid Med Cell Long. 2019; 2019: 7495629.

[26] Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020; 34(23-24): 1565-1576.

[27] Kang C, Xu Q, Martin TD, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science. 2015; 349(6255): aaa5612.

[28] Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017; 21: 21-28.

[29] Wang T, Huang S, He C. Senescent cells: a therapeutic target for osteoporosis. Cell Prolif. 2022:e13323.

[30] Elsherbiny NM, Said E, Atef H, Zaitone SA. Renoprotective effect of calycosin in high fat diet-fed/STZ injected rats: effect on IL-33/ST2 signaling, oxidative stress and fibrosis suppression. Chem Biol Interact. 2020; 315: 108897.

[31] Sehnine M, Ferhat M, Sena S, et al. IL-33 receptor ST2 deficiency attenuates renal ischaemia-reperfusion injury in euglycaemic, but not streptozotocin-induced hyperglycaemic mice. Diabetes Metab. 2018; 44(1): 55-60.

[32] Liu T, Jin YQ, Wang Q, et al. IL-33/ST2L signaling alleviates diabetic nephropathy by regulating endoplasmic reticulum stress and apoptosis. BMC Nephrology. 2023; 24(1): 361.

[33] Dwyer GK, D’Cruz LM, Turnquist HR. Emerging functions of IL-33 in homeostasis and immunity. Annu Rev Immunol. 2022; 40: 15-43.

[34] de Oliveira MFA, Talvani A, Rocha-Vieira E. IL-33 in obesity: where do we go from here?. Inflamm Res. 2019; 68(3): 185-194.

[35] Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021; 9(11): 1288-1298.

[36] Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021; 385(18): 1656-1668.

[37] Tan XY, Jing HY, Ma YR. Interleukin-33/suppression of tumorigenicity 2 in renal fibrosis: emerging roles in prognosis and treatment. Front Physiol. 2021; 12: 792897.

[38] Hofherr A, Liarte Marin E, Musial B, et al. Inhibition of interleukin-33 to reduce glomerular endothelial inflammation in diabetic kidney disease. Kidney Int Rep. 2024; 9(6): 1876-1891.

[39] Fang Y, Zhao L, Xiao H, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol. 2017; 34(2): 23.

[40] Tominaga S, Tago K, Tsuda H, Komine M. Dual function of IL-33 on proliferation of NIH-3T3 cells. Cytokine. 2015; 72(1): 105-108.

[41] Wang S, Zhao G, Zhao S, Qiao Y, Yang H. The effects of interleukin-33 (IL-33) on osteosarcoma cell viability, apoptosis, and epithelial-mesenchymal transition are mediated through the PI3K/AKT pathway. Med Sci Monit. 2020; 26: e920766.

[42] Nayki C, Nayki U, Kulhan M, et al. The effect of diabetes on ovaries in a rat model: the role of interleukin-33 and apoptosis. Gynecol Endocrinol. 2017; 33(9): 708-711.

[43] Shelite TR, Liang Y, Wang H, et al. IL-33-dependent endothelial activation contributes to apoptosis and renal injury in orientia tsutsugamushi-infected mice. PLoS NeglTrop Dis. 2016; 10(3): e0004467.

[44] Xiao L, Luo G, Li H, Yao P, Tang Y. Dietary iron overload mitigates atherosclerosis in high-fat diet-fed apolipoprotein E knockout mice: role of dysregulated hepatic fatty acid metabolism. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(10): 159004.

[45] Wu Z, Wu B, Lv X, et al. Serumal lipidomics reveals the anti-inflammatory effect of flax lignans and sinapic acid in high-fat-diet-fed mice. J Agric Food Chem. 2021; 69(32): 9111-9123.

[46] Chen L, Wu B, Mo L, et al. Associations between biological ageing and the risk of, genetic susceptibility to, and life expectancy associated with rheumatoid arthritis: a secondary analysis of two observational studies. Lancet Healthy Longev. 2024; 5(1): e45-e55.

[47] Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018; 562(7726): 203-209.

[48] Wu Y, Xiong T, Tan X, Chen L. Frailty and risk of microvascular complications in patients with type 2 diabetes: a population-based cohort study. BMC Med. 2022; 20(1): 473.

[49] Cui F, Sun Y, Xie J, et al. Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis. Eur Respir J. 2022.

[50] Yurekten O, Payne T, Tejera N, et al. MetaboLights: open data repository for metabolomics. Nucleic Acids Res. 2023; 52(D1): D640-D646.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.